Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 4/2016

01-04-2016 | Neurogastroenterology and Motility Disorders of the Gastrointestinal Tract (S Rao, Section Editor)

Chili Peppers, Curcumins, and Prebiotics in Gastrointestinal Health and Disease

Authors: Tanisa Patcharatrakul, Sutep Gonlachanvit

Published in: Current Gastroenterology Reports | Issue 4/2016

Login to get access

Abstract

There is growing evidence for the role of several natural products as either useful agents or adjuncts in the management of functional GI disorders (FGIDs). In this review, we examine the medical evidence for three such compounds: chili, a culinary spice; curcumin, another spice and active derivative of a root bark; and prebiotics, which are nondigestible food products. Chili may affect the pathogenesis of abdominal pain especially in functional dyspepsia and cause other symptoms. It may have a therapeutic role in FGIDs through desensitization of transient receptor potential vanilloid-1 receptor. Curcumin, the active ingredient of turmeric rhizome, has been shown in several preclinical studies and uncontrolled clinical trials as having effects on gut inflammation, gut permeability and the brain–gut axis, especially in FGIDs. Prebiotics, the non-digestible food ingredients in dietary fiber, may serve as nutrients and selectively stimulate the growth and/or activity of certain colonic bacteria. The net effect of this change on colonic microbiota may lead to the production of acidic metabolites and other compounds that help to reduce the production of toxins and suppress the growth of harmful or disease-causing enteric pathogens. Although some clinical benefit in IBS has been shown, high dose intake of prebiotics may cause more bloating from bacterial fermentation.
Literature
1.
Bohn L, Storsrud S, Tornblom H, Bengtsson U, Simren M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013;108(5):634–41.CrossRefPubMed
2.
Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome-- etiology, prevalence and consequences. Eur J Clin Nutr. 2006;60(5):667–72.CrossRefPubMed
3.
Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75.CrossRefPubMed
4.
Ferrucci LM, Daniel CR, Kapur K, Chadha P, Shetty H, Graubard BI, et al. Measurement of spices and seasonings in India: opportunities for cancer epidemiology and prevention. Asian Pac J Cancer Prev. 2010;11(6):1621–9.PubMedPubMedCentral
5.
Govindarajan VS, Sathyanarayana MN. Capsicum--production, technology, chemistry, and quality. Part V. Impact on physiology, pharmacology, nutrition, and metabolism; structure, pungency, pain, and desensitization sequences. Crit Rev Food Sci Nutr. 1991;29(6):435–74.CrossRefPubMed
6.
Domotor A, Peidl Z, Vincze A, Hunyady B, Szolcsanyi J, Kereskay L, et al. Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology. 2005;13(1-3):161–77.CrossRefPubMed
7.•
Holzer P. Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther. 2011;131(1):142–70. A recent extensive review on TRP channels in GI tract and their therapeutic potential.CrossRefPubMedPubMedCentral
8.
Guarino MP, Cheng L, Ma J, Harnett K, Biancani P, Altomare A, et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil. 2010;22(7):746–51.CrossRefPubMed
9.
Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet. 2003;361(9355):385–91.CrossRefPubMed
10.
Matsumoto K, Hosoya T, Tashima K, Namiki T, Murayama T, Horie S. Distribution of transient receptor potential vanilloid 1 channel-expressing nerve fibers in mouse rectal and colonic enteric nervous system: relationship to peptidergic and nitrergic neurons. Neuroscience. 2011;172:518–34.CrossRefPubMed
11.
Fuhrer M, Hammer J. Effect of repeated, long term capsaicin ingestion on intestinal chemo- and mechanosensation in healthy volunteers. Neurogastroenterol Motil. 2009;21(5):521–7.CrossRefPubMed
12.
Voight EA, Kort ME. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature. Expert Opin Ther Pat. 2010;20(9):1107–22.CrossRefPubMed
13.
Chen CL, Yi CH, Liu TT. Comparable effects of capsaicin-containing red pepper sauce and hydrochloric acid on secondary peristalsis in humans. J Gastroenterol Hepatol. 2013;28(11):1712–6.CrossRefPubMed
14.
Herrera-Lopez JA, Mejia-Rivas MA, Vargas-Vorackova F, Valdovinos-Diaz MA. Capsaicin induction of esophageal symptoms in different phenotypes of gastroesophageal reflux disease. Rev Gastroenterol Mex. 2010;75(4):396–404.PubMed
15.
Kindt S, Vos R, Blondeau K, Tack J. Influence of intra-oesophageal capsaicin instillation on heartburn induction and oesophageal sensitivity in man. Neurogastroenterol Motil. 2009;21(10):1032–9.CrossRefPubMed
16.
Liu TT, Yi CH, Lei WY, Hung XS, Yu HC, Chen CL. Influence of repeated infusion of capsaicin-contained red pepper sauce on esophageal secondary peristalsis in humans. Neurogastroenterol Motil. 2014;26(10):1487–93.CrossRefPubMed
17.
Touska F, Marsakova L, Teisinger J, Vlachova V. A "cute" desensitization of TRPV1. Curr Pharm Biotechnol. 2011;12(1):122–9.CrossRefPubMed
18.
Liu B, Zhang C, Qin F. Functional recovery from desensitization of vanilloid receptor TRPV1 requires resynthesis of phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005;25(19):4835–43.CrossRefPubMed
19.
Shima T, Shiina T, Naitou K, Nakamori H, Shimizu Y. Functional roles of capsaicin-sensitive intrinsic neural circuit in the regulation of esophageal peristalsis in rats: in vivo studies using a novel method. Am J Physiol Gastrointest Liver Physiol. 2014;306(9):G811–8.CrossRefPubMed
20.
Smid SD, Blackshaw LA. Neuromuscular function of the human lower oesophageal sphincter in reflux disease and Barrett's oesophagus. Gut. 2000;46(6):756–61.CrossRefPubMedPubMedCentral
21.
Gonzalez R, Dunkel R, Koletzko B, Schusdziarra V, Allescher HD. Effect of capsaicin-containing red pepper sauce suspension on upper gastrointestinal motility in healthy volunteers. Dig Dis Sci. 1998;43(6):1165–71.CrossRefPubMed
22.
Chen CL, Liu TT, Yi CH, Orr WC. Effects of capsaicin-containing red pepper sauce suspension on esophageal secondary peristalsis in humans. Neurogastroenterol Motil. 2010;22(11):1177–82.CrossRefPubMed
23.
Lee KJ, Vos R, Tack J. Effects of capsaicin on the sensorimotor function of the proximal stomach in humans. Aliment Pharmacol Ther. 2004;19(4):415–25.CrossRefPubMed
24.
Hammer J, Vogelsang H. Characterization of sensations induced by capsaicin in the upper gastrointestinal tract. Neurogastroenterol Motil. 2007;19(4):279–87.CrossRefPubMed
25.
Tache Y, Pappas T, Lauffenburger M, Goto Y, Walsh JH, Debas H. Calcitonin gene-related peptide: potent peripheral inhibitor of gastric acid secretion in rats and dogs. Gastroenterology. 1984;87(2):344–9.PubMed
26.
Raimura M, Tashima K, Matsumoto K, Tobe S, Chino A, Namiki T, et al. Neuronal nitric oxide synthase-derived nitric oxide is involved in gastric mucosal hyperemic response to capsaicin in rats. Pharmacology. 2013;92(1-2):60–70.CrossRefPubMed
27.
Patcharatrakul T, Gonlachanvit S. Gastroesophageal reflux symptoms in typical and atypical GERD: roles of gastroesophageal acid refluxes and esophageal motility. J Gastroenterol Hepatol. 2014;29(2):284–90.CrossRefPubMed
28.
He J, Ma X, Zhao Y, Wang R, Yan X, Yan H, et al. A population-based survey of the epidemiology of symptom-defined gastroesophageal reflux disease: the Systematic Investigation of Gastrointestinal Diseases in China. BMC Gastroenterol. 2010;10:94.CrossRefPubMedPubMedCentral
29.
Geratikornsupuk N, Chaiwatanarat T, Gonlachanvit S. Effects of capsaicin containing chili on gastroesophageal acid refluxes (GER) and gastric emptying (GE) in patients with gastroesophageal reflux symptoms. J Gastroenterol Hepatol. 2008;23:A5.
30.
Kriengkirakul C, Vasavid P, Gonlachanvit S. Chili induces epigastrium burning symptom in non-erosive reflux disease (NERD) with no effect on gastric accommodation (GA). J Gastroenterol Hepatol. 2010;25:A14.CrossRef
31.
Jutaghokiat S, Imraporn B, Gonlachanvit S. Chili improves gastroesophageal reflux symptoms in patients with Non Erosive Gastroesophageal Reflux Disease (NERD). Gastroenterology. 2009;136(5):A92.CrossRef
32.
Grossi L, Cappello G, Marzio L. Effect of an acute intraluminal administration of capsaicin on oesophageal motor pattern in GORD patients with ineffective oesophageal motility. Neurogastroenterol Motil. 2006;18(8):632–6.CrossRefPubMed
33.
Kiraly A, Suto G, Czimmer J, Horvath OP, Mozsik G. Failure of capsaicin-containing red pepper sauce suspension to induce esophageal motility response in patients with Barrett's esophagus. J Physiol Paris. 2001;95(1-6):197–200.CrossRefPubMed
34.•
Fuhrer M, Vogelsang H, Hammer J. A placebo-controlled trial of an oral capsaicin load in patients with functional dyspepsia. Neurogastroenterol Motil. 2011;23(10):918–e397. This study demonstrated visceral hypersensitivity to capsaicin in functional dyspepsia.CrossRefPubMed
35.
Patcharatrakul T, Singhagowinta P, Kullavanijaya P, Gonlachanvit S. Gastrointestinal (GI) symptoms induced by spicy, sour, and fatty food ingestion in Functional Dyspepsia (FD): a difference between Epigastric Pain Syndrome (EPS) and Postprandial Distress Syndrome (PDS). Gastroenterology. 2013;144(5):S549–50.CrossRef
36.
Bortolotti M, Coccia G, Grossi G, Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther. 2002;16(6):1075–82.CrossRefPubMed
37.
Gonlachanvit S, Fongkam P, Wittayalertpanya S, Kullavanijaya P. Red chili induces rectal hypersensitivity in healthy humans: possible role of 5HT-3 receptors on capsaicin-sensitive visceral nociceptive pathways. Aliment Pharmacol Ther. 2007;26(4):617–25.CrossRefPubMed
38.
Hayashi K, Shibata C, Nagao M, Sato M, Kakyo M, Kinouchi M, et al. Intracolonic capsaicin stimulates colonic motility and defecation in conscious dogs. Surgery. 2010;147(6):789–97.CrossRefPubMed
39.
Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. Neurogastroenterol Motil. 2009;21(1):23–32.CrossRefPubMed
40.
Agarwal MK, Bhatia SJ, Desai SA, Bhure U, Melgiri S. Effect of red chillies on small bowel and colonic transit and rectal sensitivity in men with irritable bowel syndrome. Indian J Gastroenterol. 2002;21(5):179–82.PubMed
41.
Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008;57(7):923–9.CrossRefPubMedPubMedCentral
42.
Schmulson MJ, Valdovinos MA, Milke P, Zubiran S. Chili pepper and rectal hypera gesia in irritable bowel syndrome. Am J Gastroenterol. 2003;98(5):1214–5.CrossRefPubMed
43.
Aniwan S, Gonlachanvit S. Effects of chili treatment on gastrointestinal and rectal sensation in diarrhea-predominant irritable bowel syndrome: a randomized, double-blinded, crossover study. J Neurogastroenterol Motil. 2014;20(3):400–6. This study demonstrated desensitization effect of 6-week chili ingestion on upper and lower GI symptoms in IBS-D patients.CrossRefPubMedPubMedCentral
44.
Bortolotti M, Porta S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig Dis Sci. 2011;56(11):3288–95.CrossRefPubMed
45.
46.
Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10, CD008424.PubMedPubMedCentral
47.
Thong-Ngam D, Choochuai S, Patumraj S, Chayanupatkul M, Klaikeaw N. Curcumin prevents indomethacin-induced gastropathy in rats. World J Gastroenterol. 2012;18(13):1479–84.CrossRefPubMedPubMedCentral
48.
Gupta SC, Tyagi AK, Deshmukh-Taskar P, Hinojosa M, Prasad S, Aggarwal BB. Downregulation of tumor necrosis factor and other proinflammatory biomarkers by polyphenols. Arch Biochem Biophys. 2014;559:91–9.CrossRefPubMed
49.
Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169(8):1672–92.CrossRefPubMedPubMedCentral
50.
Liu L, Liu YL, Liu GX, Chen X, Yang K, Yang YX, et al. Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway. Int Immunopharmacol. 2013;17(2):314–20.CrossRefPubMed
51.
Zeng Z, Zhan L, Liao H, Chen L, Lv X. Curcumin improves TNBS-induced colitis in rats by inhibiting IL-27 expression via the TLR4/NF-kappaB signaling pathway. Planta Med. 2013;79(2):102–9.PubMed
52.
Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion. 2012;85(4):249–55.CrossRefPubMed
53.
Wang N, Wang G, Hao J, Ma J, Wang Y, Jiang X, et al. Curcumin ameliorates hydrogen peroxide-induced epithelial barrier disruption by upregulating heme oxygenase-1 expression in human intestinal epithelial cells. Dig Dis Sci. 2012;57(7):1792–801.CrossRefPubMed
54.
De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother. 2009;53(4):1592–7.CrossRefPubMedPubMedCentral
55.
Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Commun. 2004;316(4):1065–72.CrossRefPubMed
56.
Rai D, Singh JK, Roy N, Panda D. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. Biochem J. 2008;410(1):147–55.CrossRefPubMed
57.
Han C, Wang L, Yu K, Chen L, Hu L, Chen K, et al. Biochemical characterization and inhibitor discovery of shikimate dehydrogenase from Helicobacter pylori. FEBS J. 2006;273(20):4682–92.CrossRefPubMed
58.
Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T. Effect of dietary turmeric on breath hydrogen. Dig Dis Sci. 2009;54(8):1725–9.CrossRefPubMed
59.
Yu Y, Wu S, Li J, Wang R, Xie X, Yu X, et al. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. Metab Brain Dis. 2015;31(1):47–55.CrossRef
60.
Hurley LL, Akinfiresoye L, Nwulia E, Kamiya A, Kulkarni AA, Tizabi Y. Antidepressant-like effects of curcumin in WKY rat model of depression is associated with an increase in hippocampal BDNF. Behav Brain Res. 2013;239:27–30.CrossRefPubMedPubMedCentral
61.
Rinwa P, Kumar A, Garg S. Suppression of neuroinflammatory and apoptotic signaling cascade by curcumin alone and in combination with piperine in rat model of olfactory bulbectomy induced depression. PLoS One. 2013;8(4), e61052.CrossRefPubMedPubMedCentral
62.
Tajik H, Tamaddonfard E, Hamzeh-Gooshchi N. The effect of curcumin (active substance of turmeric) on the acetic acid-induced visceral nociception in rats. Pak J Biol Sci. 2008;11(2):312–4.CrossRefPubMed
63.•
Zhi L, Dong L, Kong D, Sun B, Sun Q, Grundy D, et al. Curcumin acts via transient receptor potential vanilloid-1 receptors to inhibit gut nociception and reverses visceral hyperalgesia. Neurogastroenterol Motil. 2013;25(6):e429–40. An animal study which demonstrated a mechanism of intestinal anti-nociception of curcumin via TRPV-1 receptors.CrossRefPubMed
64.
Aldini R, Budriesi R, Roda G, Micucci M, Ioan P, D'Errico-Grigioni A, et al. Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effect. PLoS One. 2012;7(9), e44650.CrossRefPubMedPubMedCentral
65.
Gilani AH, Shah AJ, Ghayur MN, Majeed K. Pharmacological basis for the use of turmeric in gastrointestinal and respiratory disorders. Life Sci. 2005;76(26):3089–105.CrossRefPubMed
66.
Xu L, Li Z, Guo F. Curcumin improves expression of ghrelin through attenuating oxidative stress in gastric tissues of streptozotocin-induced diabetic gastroparesis rats. Eur J Pharmacol. 2013;718(1-3):219–25.CrossRefPubMed
67.
Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, et al. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter. 2007;12(3):238–43.CrossRefPubMed
68.
Lopresti AL, Maes M, Maker GL, Hood SD, Drummond PD. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J Affect Disord. 2014;167:368–75.CrossRefPubMed
69.
Sanmukhani J, Satodia V, Trivedi J, Patel T, Tiwari D, Panchal B, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014;28(4):579–85.CrossRefPubMed
70.
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.CrossRefPubMed
71.
Martin RC, Aiyer HS, Malik D, Li Y. Effect on pro-inflammatory and antioxidant genes and bioavailable distribution of whole turmeric vs curcumin: Similar root but different effects. Food Chem Toxicol. 2012;50(2):227–31.CrossRefPubMedPubMedCentral
72.
Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat. 2014;46(1):2–18.CrossRefPubMedPubMedCentral
73.
Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–54.CrossRefPubMed
74.
Roberfroid M, Gibson GR, Hoyles L, McCartney AL, Rastall R, Rowland I, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104 Suppl 2:S1–63.CrossRefPubMed
75.
Macfarlane S, Macfarlane GT, Cummings JH. Review article: prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther. 2006;24(5):701–14.CrossRefPubMed
76.
Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol. 2011;45(Suppl):S120–7.CrossRefPubMed
77.
Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012;15(5):474–9.CrossRefPubMed
78.
Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, DeRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–5.CrossRefPubMedPubMedCentral
79.
Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–50.CrossRefPubMed
80.
Nyangale EP, Mottram DS, Gibson GR. Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res. 2012;11(12):5573–85.CrossRefPubMed
81.
De Peter V, Falony G, Windey K, Hamer HM, De Vuyst L, Verbeke K. The prebiotic, oligofructose-enriched inulin modulates the faecal metabolite profile: an in vitro analysis. Mol Nutr Food Res. 2010;54(12):1791–801.CrossRef
82.
Walker WA, Iyengar RS. Breast milk, microbiota, and intestinal immune homeostasis. Pediatr Res. 2015;77(1-2):220–8.PubMed
83.
Cederlund A, Kai-Larsen Y, Printz G, Yoshio H, Alvelius G, Lagercrantz H, et al. Lactose in human breast milk an inducer of innate immunity with implications for a role in intestinal homeostasis. PLoS One. 2013;8(1), e53876.CrossRefPubMedPubMedCentral
84.
Ohman L, Simren M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep. 2013;15(5):323.CrossRefPubMed
85.
Paineau D, Payen F, Panserieu S, Coulombier G, Sobaszek A, Lartigau I, et al. The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr. 2008;99(2):311–8.CrossRefPubMed
86.
Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29(5):508–18.CrossRefPubMed
87.
Hunter JO, Tuffnell Q, Lee AJ. Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr. 1999;129(7 Suppl):1451S–3.PubMed
88.
Olesen M, Gudmand-Hoyer E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr. 2000;72(6):1570–5.PubMed
89.•
Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93–100. A randomized cross-over study demonstrated that a 21-day low FODMAP intake had effects on gut microbiota composition.CrossRefPubMed
90.
91.
Backhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. 2012;12(5):611–22.CrossRefPubMed
Metadata
Title
Chili Peppers, Curcumins, and Prebiotics in Gastrointestinal Health and Disease
Authors
Tanisa Patcharatrakul
Sutep Gonlachanvit
Publication date
01-04-2016
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 4/2016
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-016-0494-0

Other articles of this Issue 4/2016

Current Gastroenterology Reports 4/2016 Go to the issue

Nutrition and Obesity (SA McClave, Section Editor)

Can Nutritional Assessment Tools Predict Response to Nutritional Therapy?

Nutrition and Obesity (SA McClave, Section Editor)

Vitamin D Status and Supplementation in the Critically Ill

Small Intestine (D Sachar, Section Editor)

Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD)

Pediatric Gastroenterology (SR Orenstein, Section Editor)

Pain Measurement in Children with Functional Abdominal Pain

Small Intestine (D Sachar, Section Editor)

Small Bowel Congenital Anomalies: a Review and Update
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits